INTRODUCTION {#sec1-1}
============

Clinical laboratory results continue to be a vital component of patient management. While most laboratory results are not life threatening, certain results need to be promptly reported to the individuals managing patient care.\[[@ref1]\] These urgent laboratory results are called "critical values" and are defined as an abnormal value that suggests a life-threatening pathophysiologic state unless urgent care is provided.\[[@ref2][@ref3]\] Critical values have been shown to be associated with advent adverse patient events in the clinical setting.\[[@ref4]\] In recent years, the Joint Commission has promoted proper reporting of critical values as a requirement for quality healthcare.\[[@ref5]\] Efficient application and reporting of critical value limits positively impact patient outcomes by ensuring that laboratory results with potentially rapid morbid and/or life-threatening consequences reach the clinician in a timely manner. The College of American Pathologists (CAP) Q-probe study concluded that 65% of reported critical values resulted in a change in therapy.\[[@ref2]\]

Although guidelines for determining critical values have been proposed, a 1997 survey revealed that almost half of laboratories do not have any formal policies for establishing and reviewing critical value parameters.\[[@ref6]\] More recent surveys have identified a variety of modalities that are utilized in establishing critical values which include, but are not limited to, published literature, medical staff recommendations, manufacturer recommendations, internal validation of critical value limits, and adoption of values from other laboratories.\[[@ref2][@ref7]--[@ref9]\] The Joint Commission\'s designation of critical value reporting as a national patient safety goal has increased focus on proper critical value utilization.\[[@ref10]\] Therapeutic drugs have become a mainstay in patient treatment and monitoring their levels represents a significant portion of laboratory testing. Adverse effects associated with inappropriate drug dosing and subsequent toxicity range from mild to potentially lethal. Thus, critical values provide a safety net to clinicians striving to avoid prolonged exposure of patients to inappropriate drug concentrations. In the case of therapeutic drugs, critical value limits are often established with regard to dangerously high drug concentrations. In this study, the critical value concentration limit refers to the lowest drug concentration that is reported as a critical result.

While many laboratories utilize critical values in the reporting of therapeutic drug levels, there is limited literature available regarding absolute levels and interlaboratory variation. One study reviewed nine United States Veterans Administration medical centers and summarized the marked variation in therapeutic drug critical values.\[[@ref11]\] A study of 19 pediatric institutions in Canada also demonstrated large variation in pediatric therapeutic drug critical values.\[[@ref12]\] Not only is there wide variation in the reported critical value drug concentration limits, but there is also disparity in the therapeutic drugs that are associated with critical values.\[[@ref7]\] In response to these discrepancies, there have been calls for the adoption of more standardized critical values.\[[@ref9][@ref11]\]

Although critical values should be clearly defined in laboratory operating procedures and medical record reporting, some laboratories also choose to publish online critical value lists. While these values can be accessed by laboratory staff, patient care providers, and patients, it is not entirely clear how this information is being utilized. For better or worse, physicians and medical staff have been demonstrated to utilize public web-based resources and search engines for assistance in clinical decision making.\[[@ref13]--[@ref15]\] The degree to which web-based publications of critical value limits influence clinical practice or result interpretation is unknown. Furthermore, Internet accessible critical values allow for interlaboratory comparison when establishing or altering one\'s critical value limits. Various laboratories have reported using critical values from established laboratories as a factor in setting their own critical value limits.\[[@ref7]\] Thus, reference to critical value limits in a public online setting may influence the establishment of critical value limits in other institutions. It has been suggested that surveying critical value limits could assist in the establishment of more uniform and safe critical value limits, as well as in the optimization of effective critical value reporting systems.\[[@ref7][@ref9][@ref11]\]

In order to evaluate the degree in variation and consistency of existing online critical values for therapeutic drug monitoring, a web-based review of laboratory critical value limits for therapeutic drugs was initiated. While a significant proportion of commercial, government, and university-based laboratories publish critical value limits online, the target population of this study was all United States clinical laboratories associated with the Accreditation Council for Graduate Medical Education (ACGME) pathology residency programs. These accredited laboratories were selected for a systemic online examination of the variation of posted therapeutic drug critical values. Academic institutions with pathology residency programs play a significant role in training the next generation of physicians and laboratory directors, and often also serve as commercial referral resources for community-based laboratories and medical institutions.

MATERIALS AND METHODS {#sec1-2}
=====================

In August 2009, personal computers of the authors were used to investigate a set of 107 university-based core clinical laboratories that were associated with United States pathology residency programs. This study was limited to academic hospitals with pathology residency programs. Commercial reference laboratories without associated pathology residency programs were not surveyed; however, many of the academic institutions in this study concurrently offer reference laboratory services. The search engine Google was used to identify these university-based core clinical laboratories and the publicly available critical values were collected by searching the laboratory websites. This study was performed at the University of Arkansas for Medical Sciences. Of the 107 programs, 36 of the clinical laboratories had Internet accessible published critical value limits for therapeutic drugs. The critical values were manually recorded into Excel using each individual program\'s units. These values were then converted to the International System of Units (SI) by applying commonly used conversion factors. To further analyze these values, Excel was utilized to calculate the median, range, standard deviation, and percent coefficient of variation for each therapeutic drug.

During the process of collecting data and converting the published critical value limits to uniform units for comparison, it became apparent that certain reported values were absurd due to mislabeled units of measurement mentioned in the Results section. These values were deemed erroneous and were not utilized in further analysis. For the 36 institutions, the percentage of laboratories reporting each drug and the percentage of laboratories with absurd results were calculated.

Variation in critical value limits between laboratories could represent true differences in practice or could be reflective of assay-specific analytical differences. In order to account for such analytical potential variation, the CAP 2009 Participant Summary "B" Survey of Chemistry/Therapeutic Drug Monitoring was utilized as a reference to gauge interassay variation. For this approach, a single CAP survey challenge sample was selected for each analyte that measured values closest to the critical value limit concentration for each therapeutic drug. By identifying the variability in survey challenge samples, the acceptable intrinsic laboratory assay variability was established and provided a measure of variation in therapeutic drugs due to assay differences. For a single challenge sample, both the range of all assay reported instrument means and the mean coefficient of variation between all reported instruments were determined. These values were compared to the range and coefficient of variation for published critical values collected in this study.

RESULTS {#sec1-3}
=======

There was wide variation among the 36 laboratories that published Internet accessible critical values for therapeutic drugs, see [Table 1](#T1){ref-type="table"}. Multifold differences were observed for many therapeutic drugs, indicating a high degree of variance and a lack of standardization. In most cases, the relative coefficient of variation was greater than or equal to 20%.

###### 

Therapeutic drug concentration critical value distribution for 36 institutions with publicly available critical values lists and accredited pathology residency training programs

![](JPI-2-53-g001)

Nearly all programs with online published critical values reported critical values for antiepileptics and other commonly toxic drugs such as digoxin, lithium, salicylate, and theophylline. Fewer institutions had critical values for antibiotic monitoring with vancomycin being the most frequently reported. The percentage of total institutions reporting critical values for each analyte and specified sample type is provided in [Table 2](#T2){ref-type="table"}.

###### 

Percentage of laboratories publishing critical values for each therapeutic drug
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Several analytes in this study exhibited critical value limits linked to the time of specimen collection. While some institutions reported both peak and trough critical values for antibiotics, others specified only peak or trough critical values. Another example was the reporting of acetaminophen critical values. Although all 36 institutions reported critical values for acetaminophen, 26 did not specify the time after acetaminophen ingestion, four only reported a value for 4 hours postingestion, and six reported values for both 4 and 12 hours postingestion.

As described previously, several absurd critical values were reported on the websites of the laboratories and were not included in further data evaluation. Most of these values appeared to result from the publication of erroneous units of measurement. All critical value limits deemed absurd are listed in [Table 3](#T3){ref-type="table"}.

###### 

Absurd Internet-published critical value limits
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Interassay differences for each drug are a potential cause of the observed wide variation in therapeutic drug monitoring critical value limits. To evaluate this possibility, the CAP 2009 Participant Summary "B" Survey of Chemistry/Therapeutic Drug Monitoring was utilized. This document details the reported values for each analyte as determined by different instruments. [Table 4](#T4){ref-type="table"} illustrates that the range and coefficient of variation of critical values reported for each drug by the different university-based institutions were often substantially greater than the interinstrument mean values demonstrated by CAP proficiency testing.

###### 

Range of reported means and coefficients of variation for different instruments in CAP proficiency testing
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DISCUSSION {#sec1-4}
==========

While many of the laboratories in our study consistently reported critical values on similar sets of therapeutic drugs, there was a large degree of observed heterogeneity in critical value limits. Previous studies have indicated significant variation in critical values limits for chemistry and hematology analytes.\[[@ref5][@ref7][@ref9][@ref12]\] Although fewer publications have focused on therapeutic drug monitoring critical values, the small number of existing targeted surveys have also indicated a gross lack of standardization.\[[@ref11][@ref12]\] Not only does our study support these previous results, but also demonstrates the presence of significant discrepancies between academic training hospitals.

This study yielded other notable observations regarding utilization of critical value limits \[[Table 1](#T1){ref-type="table"}\]. While acetaminophen critical values were reported by all institutions, they fell into three categories: 4 hours postingestion, 12 hours postingestion, and time unspecified. Time-dependent nomograms utilize serum concentrations to evaluate for acetaminophen toxicity. Yet in our study, 26 of 37 institutions do not utilize time of ingestion when establishing critical values limits. Additionally, multiple laboratories reported vancomycin critical value limits for both peak and trough determinations. While utilized in the past, recent reports have concluded that peak serum vancomycin concentrations should not be used to monitor for nephrotoxicity with the determination of trough concentrations being preferable.\[[@ref15][@ref16]\]

Despite recommendations that phenytoin toxicity be preferentially monitored by assays for the free form, less than half of the studied institutions reporting a critical value for total phenytoin had a corresponding value for free phenytoin.\[[@ref16]\] This antiepileptic is almost completely protein bound with only a small fraction of the active free drug present. Renal failure, the alteration of albumin and total protein levels, and the presence of other highly protein bound drugs can affect the protein binding of phenytoin.\[[@ref17]\] This has been shown to occur in at-risk patient populations such as the critically ill and children.\[[@ref17][@ref18]\]

Interassay differences are a potential contributor to variation in critical value limits. In almost all cases, the identity of the testing analyzer associated with specific critical value limits was not published online. Unlike many other common chemistry analytes, CAP proficiency reports (with the exception of lithium) do not include "all method principles-all instruments" means and coefficients of variation for therapeutic drugs. The "all method" means and coefficients of variation are generated directly from data collected at all proficiency sites. These data could be used to compare the relative variation in proficiency testing to the variation observed in published critical value limits and would allow one to assess the degree to which interassay variation might contribute to critical value limit variation.

In the absence of the "all methods" variation metric, the CAP range of means and coefficient of variation for all instrument means calculated for a single proficiency challenge sample were compared to the data obtained from the web-based review of laboratories \[[Table 4](#T4){ref-type="table"}\]. For most drugs, the relative range and mean coefficient of variation of published critical values substantially exceeded relative differences observed in proficiency testing. This strongly implies that the observed variation in critical value limits is not predominantly due to differences in analytical methodology.

However, as is shown in [Table 4](#T4){ref-type="table"}, significant interinstrument differences do exist for some therapeutic drugs and this likely does contribute to a degree to the variation in critical value concentration limits. Reduction in interassay differences by the manufacturer may improve agreement of critical value concentration limits. Publication of "all method" means and coefficients of variation in proficiency testing reports may further encourage harmonization of assays.

There are several other potential causes of variation in critical value limits observed in our study, which include population diversity and tailored clinical standards of practice and notification.\[[@ref3]\] Extensive utilization and reporting of critical values requires significant investment of labor resources. Thus, some institutions may adopt relatively elevated critical values limits in order to reduce the volume of critical value calls.\[[@ref11]\] Additionally, institutions may adopt unusual critical values to reflect clinical predominance of certain disease states or to support specific treatment protocols. Clinical management philosophies for a particular condition may vary depending on a hospital\'s expertise and familiarization with the disease and therapeutic agents. Further evaluation of the factors affecting the critical value heterogeneity between laboratories is essential in establishing an evidence-based standard.\[[@ref1][@ref11]\]

To our knowledge, this study is the first to comment on public Internet-based accessible critical value limits. A significant portion (one-third) of the laboratories investigated in this study chose to publish online critical value limits for therapeutic drug monitoring. Multiple apparent errors in published lists of critical value limits were observed \[[Table 3](#T3){ref-type="table"}\]. Presumably, these errors are not incorporated into the formal reporting of patient results. While the publication of critical value lists may provide an accessible reference to healthcare providers, the potential for error in the production of these online lists clearly does exist. The impact of these erroneous published critical value limits on patient care is not known, but it is plausible that clinical treatment might be inappropriately influenced by an incorrect web-based critical value limit. Institutions should consider the potential benefits of publishing web-based critical values versus deleterious effects related to the potential for erroneous reporting of these values. As pathology informatics continue to migrate toward direct reporting of laboratory data, accuracy must be maintained in supporting web-based documentation.

Our study illustrates that relatively little progress has been made in recent decades in implementation of more consistent critical value limits for therapeutic drug monitoring. A 1992 attempt to compile a comprehensive list of critical values in over 600 laboratories was discontinued due to "astounding" diversity, most notably in therapeutic drug monitoring.\[[@ref11][@ref19]\] Diversity of critical value limits is not unique to the United States.\[[@ref9][@ref12]\] For example, a report on a survey of critical limits in United Kingdom laboratories concluded that therapeutic critical value limits set by some laboratories "do not appear to be related to clinical toxicology."\[[@ref8]\] Our study does not recommend specific critical value limits and does not indicate the practical presence of consensus-based recommendations for critical value limits in the laboratories surveyed. A wide body of literature has previously addressed the toxic concentrations and resulting clinical consequences for many therapeutic drugs.\[[@ref20]\] However, there is no current universal authoritative source for critical value limits.\[[@ref9]\]

In summary, the results of this web-based review demonstrate that publicly available established critical values for therapeutic drugs exhibit significant variation between academic laboratories. This variation does not appear to be predominantly caused by differences in assay methodology, as demonstrated by comparison to CAP proficiency testing results. Laboratories should consider the merits of publishing their critical values and work to eliminate errors in reporting online critical value limits. This study illustrates current interlaboratory discrepancies amongst academic laboratories with regard to published therapeutic drug critical value reporting, and may provide further impetus to calls for standardization of critical value limits.
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